Clostridium Difficile Vaccine Efficacy Trial

NCT03090191

Last updated date
Study Location
North Alabama Research Center, LLC
Athens, Alabama, 35611, United States
Contact
1-800-718-1021

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Clostridium Difficile Infection
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
50 + years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Evidence of a personally signed and dated informed consent document.

- Willing and able to comply with study procedures.

- Subjects with an increased risk of future contact with healthcare systems or subjects who have received systemic antibiotics in the previous 12 weeks.

- Ability to be contacted by telephone during study participation.

- Negative urine pregnancy test for female subjects of childbearing potential.

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- Investigator site staff members directly involved in the conduct of the study and
their family members, site staff members otherwise supervised by the investigator, or
subjects who are Pfizer employees, including their family members, directly involved
in the conduct of the study.


- Participation in other studies involving investigational drug(s)/vaccine(s) within 28
days prior to study entry until 1 month after the third vaccination.


- Previous administration of an investigational C difficile vaccine or C difficile mAb
therapy.


- Prior episode of CDI..


- Receipt of blood products or immunoglobulins within 6 months before enrollment.


- Subjects who may be unable to respond to vaccination due to:


- Metastatic malignancy; or


- End-stage renal disease; or


- Any serious medical disorder likely to be fatal within the next 12 months; or


- Congenital or acquired immunodeficiency; or


- Receipt of high dose systemic corticosteroids for 14 days within 28 days of
enrollment; or


- Receipt of chronic systemic treatment with other known immunosuppressant
medications, or radiotherapy, within 6 months of enrollment.


- Known infection with human immunodeficiency virus (HIV).


- Any bleeding disorder or anticoagulant therapy that would contraindicate intramuscular
injection.


- Any contraindication to vaccination or vaccine components, including previous
anaphylactic reaction to any vaccine or vaccine-related components.


- Prior small- or large-bowel resection.


- Any condition or treatment resulting in frequent diarrhea.


- Other acute or chronic condition or abnormality that may increase the risk associated
with study participation or IP administration or may interfere with interpretation of
study results


- Pregnant or breastfeeding female subjects; male subjects and female subjects who are
sexually active and at risk for pregnancy and will not/cannot use 2 methods of
contraception

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Clostridium Difficile InfectionClostridium Difficile Vaccine Efficacy Trial
NCT03090191
  1. Athens, Alabama
  2. Huntsville, Alabama
  3. Mobile, Alabama
  4. Peoria, Arizona
  5. Phoenix, Arizona
  6. Phoenix, Arizona
  7. Phoenix, Arizona
  8. Phoenix, Arizona
  9. Phoenix, Arizona
  10. Surprise, Arizona
  11. Little Rock, Arkansas
  12. North Little Rock, Arkansas
  13. Banning, California
  14. Daly City, California
  15. Downey, California
  16. Loma Linda, California
  17. Long Beach, California
  18. Long Beach, California
  19. Long Beach, California
  20. Los Angeles, California
  21. Los Angeles, California
  22. Los Angeles, California
  23. Los Angeles, California
  24. Mather, California
  25. Oakland, California
  26. Palo Alto, California
  27. Rancho Mirage, California
  28. Redding, California
  29. Roseville, California
  30. Sacramento, California
  31. Sacramento, California
  32. Sacramento, California
  33. Sacramento, California
  34. Sacramento, California
  35. Sacramento, California
  36. San Bernardino, California
  37. San Diego, California
  38. San Diego, California
  39. San Dimas, California
  40. San Jose, California
  41. Santa Clara, California
  42. Simi Valley, California
  43. Walnut Creek, California
  44. Aurora, Colorado
  45. Aurora, Colorado
  46. Aurora, Colorado
  47. Aurora, Colorado
  48. Hamden, Connecticut
  49. Hamden, Connecticut
  50. Milford, Connecticut
  51. Bay Pines, Florida
  52. Brandon, Florida
  53. Brandon, Florida
  54. Chiefland, Florida
  55. Clearwater, Florida
  56. Coral Gables, Florida
  57. Coral Gables, Florida
  58. DeLand, Florida
  59. Fleming Island, Florida
  60. Gainesville, Florida
  61. Gainesville, Florida
  62. Hialeah, Florida
  63. Jacksonville, Florida
  64. Lake City, Florida
  65. Lauderdale Lakes, Florida
  66. Miami Springs, Florida
  67. Miami, Florida
  68. Miami, Florida
  69. Miami, Florida
  70. Miami, Florida
  71. Naples, Florida
  72. Orlando, Florida
  73. Orlando, Florida
  74. Orlando, Florida
  75. Pembroke Pines, Florida
  76. Port Orange, Florida
  77. West Palm Beach, Florida
  78. Decatur, Georgia
  79. Savannah, Georgia
  80. Stockbridge, Georgia
  81. Honolulu, Hawaii
  82. Idaho Falls, Idaho
  83. Meridian, Idaho
  84. Meridian, Idaho
  85. Champaign, Illinois
  86. Hines, Illinois
  87. Springfield, Illinois
  88. Springfield, Illinois
  89. Anderson, Indiana
  90. Carmel, Indiana
  91. Carmel, Indiana
  92. Evansville, Indiana
  93. Indianapolis, Indiana
  94. Mishawaka, Indiana
  95. Wichita, Kansas
  96. Bardstown, Kentucky
  97. Lexington, Kentucky
  98. Marrero, Louisiana
  99. Metairie, Louisiana
  100. Natchitoches, Louisiana
  101. New Orleans, Louisiana
  102. New Orleans, Louisiana
  103. Annapolis, Maryland
  104. Annapolis, Maryland
  105. Annapolis, Maryland
  106. Annapolis, Maryland
  107. Ann Arbor, Michigan
  108. Canton, Michigan
  109. Flint, Michigan
  110. Sterling Heights, Michigan
  111. Rochester, Minnesota
  112. Rochester, Minnesota
  113. Biloxi, Mississippi
  114. Saint Louis, Missouri
  115. Saint Louis, Missouri
  116. Saint Louis, Missouri
  117. Saint Louis, Missouri
  118. Saint Louis, Missouri
  119. Saint Louis, Missouri
  120. Bozeman, Montana
  121. Butte, Montana
  122. Norfolk, Nebraska
  123. Omaha, Nebraska
  124. Omaha, Nebraska
  125. Hillsborough, New Jersey
  126. Raritan, New Jersey
  127. Somers Point, New Jersey
  128. Albuquerque, New Mexico
  129. Binghamton, New York
  130. Endwell, New York
  131. Rochester, New York
  132. Calabash, North Carolina
  133. Cary, North Carolina
  134. Cary, North Carolina
  135. Charlotte, North Carolina
  136. Durham, North Carolina
  137. Durham, North Carolina
  138. Durham, North Carolina
  139. Greensboro, North Carolina
  140. Hickory, North Carolina
  141. Raleigh, North Carolina
  142. Raleigh, North Carolina
  143. Rocky Mount, North Carolina
  144. Salisbury, North Carolina
  145. Tabor City, North Carolina
  146. Wilmington, North Carolina
  147. Winston-Salem, North Carolina
  148. Winston-Salem, North Carolina
  149. Canton, Ohio
  150. Canton, Ohio
  151. Cincinnati, Ohio
  152. Cincinnati, Ohio
  153. Cincinnati, Ohio
  154. Cincinnati, Ohio
  155. Cleveland, Ohio
  156. Cleveland, Ohio
  157. Cleveland, Ohio
  158. Columbus, Ohio
  159. Columbus, Ohio
  160. Columbus, Ohio
  161. Dayton, Ohio
  162. Mentor, Ohio
  163. Oklahoma City, Oklahoma
  164. Portland, Oregon
  165. Portland, Oregon
  166. Portland, Oregon
  167. Allentown, Pennsylvania
  168. Allentown, Pennsylvania
  169. Camp Hill, Pennsylvania
  170. Erie, Pennsylvania
  171. Erie, Pennsylvania
  172. Philadelphia, Pennsylvania
  173. Pittsburgh, Pennsylvania
  174. Pittsburgh, Pennsylvania
  175. Uniontown, Pennsylvania
  176. Warwick, Rhode Island
  177. Mount Pleasant, South Carolina
  178. Dakota Dunes, South Dakota
  179. Bristol, Tennessee
  180. Bristol, Tennessee
  181. Bristol, Tennessee
  182. Knoxville, Tennessee
  183. Knoxville, Tennessee
  184. Memphis, Tennessee
  185. Tullahoma, Tennessee
  186. Austin, Texas
  187. Dallas, Texas
  188. Fort Worth, Texas
  189. Fort Worth, Texas
  190. Galveston, Texas
  191. Houston, Texas
  192. Houston, Texas
  193. Houston, Texas
  194. Mesquite, Texas
  195. Pearland, Texas
  196. San Antonio, Texas
  197. San Antonio, Texas
  198. San Antonio, Texas
  199. Tomball, Texas
  200. Draper, Utah
  201. Riverton, Utah
  202. Salt Lake City, Utah
  203. Salt Lake City, Utah
  204. South Jordan, Utah
  205. Annandale, Virginia
  206. Midlothian, Virginia
  207. Salem, Virginia
  208. Port Orchard, Washington
  209. Puyallup, Washington
  210. Tacoma, Washington
  211. Tacoma, Washington
  212. Wenatchee, Washington
  213. Marshfield, Wisconsin
  214. Kanwal, New South Wales
  215. Maroubra, New South Wales
  216. Westmead, New South Wales
  217. Westmead, New South Wales
  218. Sherwood, Queensland
  219. South Brisbane, Queensland
  220. Box Hill, Victoria
  221. Camberwell, Victoria
  222. Geelong, Victoria
  223. Nedlands, Western Australia
  224. Dijon cedex,
  225. Paris,
  226. Saint Priest en Jarez,
  227. Tours Cedex 09,
  228. Berlin,
  229. Cottbus,
  230. Dresden,
  231. Essen,
  232. Leipzig,
  233. Leipzig,
  234. Leipzig,
  235. Rostock,
  236. Wardenburg,
  237. Westerstede,
  238. Wuerzburg,
  239. Stockport, Cheshire
  240. Fowey, Cornwall
  241. Liskeard, Cornwall
  242. Torpoint, Cornwall
  243. Exeter, Devon
  244. Plymouth, Devon
  245. Blackpool, Lancashire
  246. Leicester, Leicestershire
  247. Edinburgh, Midlothian
  248. Birmingham, WEST Midlands
  249. Leeds,
  250. Newcastle upon Tyne,
  251. Usti nad Labem,
  252. Budapest,
  253. Oulu,
  254. Rimavska Sobota,
  255. Slany,
  256. Roznov pod Radhostem,
  257. Miskolc,
  258. Trujillo, LA Libertad
  259. Piestany,
  260. Leuven,
  261. Pori,
  262. Stara Tura,
  263. Tokyo,
  264. Charleston, South Carolina
  265. Sapporo-shi, Hokkaido
  266. Barcelona,
  267. Baja,
  268. Koga, Ibaraki
  269. Incheon,
  270. Kusatsu, Shiga
  271. Bunkyo-ku, Tokyo
  272. Kaohsiung City, Taiwan (r.o.c.)
  273. Balatonfured,
  274. Buenos Aires,
  275. Sofia,
  276. Silistra,
  277. Leczna,
  278. Praha 5,
  279. Cusco,
  280. Yaizu, Shizuoka
  281. Lima,
  282. C.a.b.a., Buenos Aires
  283. Valencia,
  284. Slany,
  285. Floridablanca, Santander
  286. Dallas, Texas
  287. Seoul,
  288. New Taipei City,
  289. Tampere,
  290. Cordoba,
  291. Liege,
  292. Plovdiv,
  293. Nitra,
  294. Trencin,
  295. Chicoutimi, Quebec
  296. Fukuyama, Hiroshima
  297. Osaki, Miyagi
  298. Eskilstuna,
  299. Greenfield Park, Quebec
  300. Santiago, Región Metropolitana
  301. Madrid,
  302. Opava,
  303. Gdynia,
  304. Gdansk,
  305. Fargo, North Dakota
  306. Hospitalet de Llobregat, Barcelona
  307. A Coruna,
  308. Kaposvar,
  309. Vancouver, British Columbia
  310. Nagoya, Aichi
  311. Nove Zamky,
  312. Gatineau, Quebec
  313. Barcelona,
  314. Bojnice,
  315. Braga,
  316. Brno, Czech
  317. Policka,
  318. Daito, Osaka
  319. Matsumoto-City, Nagano Prefecture
  320. Orebro,
  321. Sliven,
  322. Toronto, Ontario
  323. Trois-Rivieres, Quebec
  324. Katowice,
  325. Seoul,
  326. Pruske,
  327. Penzance, Cornwall
  328. Maximin Liikekeskus, Kokkola
  329. Fukui,
  330. Greenfield Park, Quebec
  331. Yokosuka, Kanagawa
  332. Turku,
  333. Kazanlak,
  334. Vidin,
  335. Pleven,
  336. Nagakute, Aichi
  337. Bratislava,
  338. Madrid,
  339. Ansan, Gyeonggi-do
  340. Poznan,
  341. San Martin de Porres, Lima
  342. Medellin, Antioquia
  343. Bogota, D.c.
  344. Songpa-gu, Seoul
  345. Saint Louis, Missouri
  346. Saga,
  347. Sevlievo,
  348. Trnava,
  349. C.a.b.a., Buenos Aires
  350. Santa Fe,
  351. Budapest,
  352. Barranquilla, Atlantico
  353. Stockholm,
  354. Incheon,
  355. Gyeonggi-do,
  356. Barcelona,
  357. Busan,
  358. Veliko Tarnovo,
  359. Almada,
  360. Sevilla,
  361. Santiago, Región Metropolitana
  362. Troyan,
  363. Kozloduy,
  364. Madrid,
  365. Sofia,
  366. Cali, Valle DEL Cauca
  367. Iizuka, Fukuoka
  368. Temuco, Region DE LA Araucaria
  369. Nerima-ku, Tokyo
  370. Bydgoszcz,
  371. Göteborg,
  372. Ruse,
  373. Cali, Valle DEL Cauca
  374. Antofagasta, Region DE Antofagasta
  375. Seoul,
  376. Ottawa, Ontario
  377. Quebec,
  378. Manizales, Caldas
  379. Medellin, Antioquia
  380. Kyjov, Czech
  381. Kumamoto,
  382. Kitakyushu, Fukuoka
  383. Brussels,
  384. Quebec,
  385. Madrid,
  386. Warszawa,
  387. Kosice,
  388. Goteborg,
  389. Antofagasta, Region DE Antofagasta
  390. Ruse,
  391. Ottawa, Ontario
  392. Taipei,
  393. Daegu,
  394. Mito, Ibaraki
  395. Kasuga, Fukuoka
  396. Rosario, Santa FE
  397. Temuco, IX Region DE LA Araucania
  398. Helsinki,
  399. C.a.b.a., Buenos Aires
  400. Guimaraes,
  401. Spisska Nova Ves,
  402. Toshima-ku, Tokyo
  403. Chicago, Illinois
  404. Seoul,
  405. Sofia,
  406. Pribram I.,
  407. Medellin, Antioquia
  408. Sherbrooke, Quebec
  409. Kasugai, Aichi
  410. Debrecen,
  411. Sofia,
  412. Armenia, Quindío
  413. Trencin,
  414. Wonju-si, Gangwon-do
  415. Aveiro,
  416. Itoshima, Fukuoka
  417. Nagoya, Aichi
  418. Benatky nad Jizerou,
  419. Vila Nova de Gaia,
  420. Quebec,
  421. Centelles, Barcelona
  422. Budapest,
  423. Seoul,
  424. Wroclaw,
ALL GENDERS
50 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE Clostridium Difficile Vaccine Efficacy Trial
Official Title  ICMJE A PHASE 3, PLACEBO-CONTROLLED, RANDOMIZED, OBSERVER-BLINDED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER
Brief Summary

The Clover trial is evaluating an investigational vaccine that may help to prevent Clostridium difficile infection. Participants in the study are adults 50 years of age and older, who are at risk of developing Clostridium difficile infection. The study will assess whether the vaccine prevents the disease, and whether it is safe and well tolerated.

Each subject will receive 3 doses of Clostridium difficile vaccine or placebo and be followed for up to 3 years after vaccination for potential Clostridium difficile infection.

Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 3
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Condition  ICMJE Clostridium Difficile Infection
Intervention  ICMJE
  • Biological: Clostridium difficile vaccine
    Toxoid-based Clostridium difficile vaccine
  • Biological: Placebo
    Normal saline solution (0.9% sodium chloride)
Study Arms  ICMJE
  • Experimental: Clostridium difficile vaccine
    Intervention: Biological: Clostridium difficile vaccine
  • Placebo Comparator: Placebo
    Intervention: Biological: Placebo
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Active, not recruiting
Actual Enrollment  ICMJE
 (submitted: October 25, 2019)
17525
Original Estimated Enrollment  ICMJE
 (submitted: March 20, 2017)
15776
Estimated Study Completion Date  ICMJE September 28, 2020
Estimated Primary Completion Date September 28, 2020   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Evidence of a personally signed and dated informed consent document.
  • Willing and able to comply with study procedures.
  • Subjects with an increased risk of future contact with healthcare systems or subjects who have received systemic antibiotics in the previous 12 weeks.
  • Ability to be contacted by telephone during study participation.
  • Negative urine pregnancy test for female subjects of childbearing potential.

Exclusion Criteria:

  • Investigator site staff members directly involved in the conduct of the study and their family members, site staff members otherwise supervised by the investigator, or subjects who are Pfizer employees, including their family members, directly involved in the conduct of the study.
  • Participation in other studies involving investigational drug(s)/vaccine(s) within 28 days prior to study entry until 1 month after the third vaccination.
  • Previous administration of an investigational C difficile vaccine or C difficile mAb therapy.
  • Prior episode of CDI..
  • Receipt of blood products or immunoglobulins within 6 months before enrollment.
  • Subjects who may be unable to respond to vaccination due to:

    • Metastatic malignancy; or
    • End-stage renal disease; or
    • Any serious medical disorder likely to be fatal within the next 12 months; or
    • Congenital or acquired immunodeficiency; or
    • Receipt of high dose systemic corticosteroids for 14 days within 28 days of enrollment; or
    • Receipt of chronic systemic treatment with other known immunosuppressant medications, or radiotherapy, within 6 months of enrollment.
  • Known infection with human immunodeficiency virus (HIV).
  • Any bleeding disorder or anticoagulant therapy that would contraindicate intramuscular injection.
  • Any contraindication to vaccination or vaccine components, including previous anaphylactic reaction to any vaccine or vaccine-related components.
  • Prior small- or large-bowel resection.
  • Any condition or treatment resulting in frequent diarrhea.
  • Other acute or chronic condition or abnormality that may increase the risk associated with study participation or IP administration or may interfere with interpretation of study results
  • Pregnant or breastfeeding female subjects; male subjects and female subjects who are sexually active and at risk for pregnancy and will not/cannot use 2 methods of contraception
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 50 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE Yes
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Argentina,   Australia,   Belgium,   Bulgaria,   Canada,   Chile,   Colombia,   Czechia,   Finland,   France,   Germany,   Hungary,   Japan,   Korea, Republic of,   Peru,   Poland,   Portugal,   Slovakia,   Spain,   Sweden,   Taiwan,   United Kingdom,   United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT03090191
Other Study ID Numbers  ICMJE B5091007
2016-003866-14 ( EudraCT Number )
CLOVER ( Other Identifier: Alias Study Number )
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD:Yes
Plan Description:Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/d….
URL:https://www.pfizer.com/science/clinical_trials/trial_data_and_results/d…
Responsible Party Pfizer
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director:Pfizer CT.gov Call CenterPfizer
PRS Account Pfizer
Verification Date February 2020

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP